MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection

Liu,Wei; Wang,Na; Lu,Min; Du,Xiao‑Juan; Xing,Bao‑Cai

doi:10.3892/mmr.2016.5404

MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection

Authors:
- Wei Liu
- Na Wang
- Min Lu
- Xiao‑Juan Du
- Bao‑Cai Xing
View Affiliations

Affiliations: Hepatopancreatobiliary Surgery Department Ⅰ, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, P.R. China, Department of Cell Biology and Cancer Research Center, Peking University Health Science Center, Beijing 100083, P.R. China
Published online on: June 15, 2016 https://doi.org/10.3892/mmr.2016.5404
Pages: 1617-1623
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Methyl-CpG binding domain 2 (MBD2) leads to the silencing of methylated genes in cancer cells and was implicated in the activation of prometastatic genes in hepatocellular carcinoma (HCC). The present study aimed to investigate the expression status of MBD2 in HCC and the correlation with surgical outcomes. The correlation between clinical prognostic factors and MBD2 were also evaluated. MBD2 expression was analyzed by western blotting in 20 paired HCC and paratumor liver (PTL) tissues. In addition, immunohistochemistry was performed on the 159 HCC samples following hepatic resection performed between January 2003 and October 2008. The correlation between clinicopathological factors and MBD2 expression was also evaluated by statistical analysis to determine the prognostic value of MBD2 expression in HCC. Postoperative prognostic factors were evaluated using univariate and multivariate analyses. Compared with PTL tissues, MBD2 expression was shown to be upregulated in 10 of the 20 HCC tissues (50%) by western blotting. The immunohistochemistry data indicated significant increase of the MBD2 expression level in 81 cases (50.94%) compared with the PTL tissues (0/159, 0%, P<0.001). The upregulated MBD2 expression in HCC tissues was correlated with BCLC stage B, tumor size >5 cm and microscopic vascular invasion. Multivariate analysis revealed that MBD2 was an independent prognostic factor for overall survival [HR, 2.089; P=0.001] and disease-free survival (HR, 1.601; P=0.022). In conclusion, MBD2 expression was elevated in HCC tissue, which suggesting MBD2 as a candidate prognostic marker of HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Shimozawa N and Hanazaki K: Longterm prognosis after hepatic resection for small hepatocellular carcinoma. J Am Coll Surg. 198:356–365. 2004. View Article : Google Scholar : PubMed/NCBI
3	Verhoef C, de Man RA, Zondervan PE, Eijkemans MJ, Tilanus HW and Ijzermans JN: Good outcomes after resection of large hepatocellular carcinoma in the non-cirrhotic liver. Dig Surg. 21:380–386. 2004. View Article : Google Scholar : PubMed/NCBI
4	Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M and Broelsch CE: Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg. 205:27–36. 2007. View Article : Google Scholar : PubMed/NCBI
5	Hendrich B, Abbott C, Mcqueen H, Chambers D, Cross S and Bird A: Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3 and Mbd4 genes. Mamm Genome. 10:906–912. 1999. View Article : Google Scholar : PubMed/NCBI
6	Xiong Y, Dowdy SC, Eberhardt NL, Podratz KC and Jiang SW: hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications. Gynecol Oncol. 103:321–328. 2006. View Article : Google Scholar : PubMed/NCBI
7	Auriol E, Billard LM, Magdinier F and Dante R: Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus. Nucleic Acids Res. 33:4243–4254. 2005. View Article : Google Scholar : PubMed/NCBI
8	Mian OY, Wang SZ, Zhu SZ, Gnanapragasam MN, Graham L, Bear HD and Ginder GD: Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res. 9:1152–1162. 2011. View Article : Google Scholar : PubMed/NCBI
9	Campbell PM, Bovenzi V and Szyf M: Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis. 25:499–507. 2004. View Article : Google Scholar
10	Bakker J, Lin X and Nelson WG: Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem. 277:22573–22580. 2002. View Article : Google Scholar : PubMed/NCBI
11	Stefanska B, Suderman M, Machnes Z, Bhattacharyya B, Hallett M and Szyf M: Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein MBD2. Carcinogenesis. 34:2738–2749. 2013. View Article : Google Scholar : PubMed/NCBI
12	Ballestar E, Yusufzai TM and Wolffe AP: Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. Biochemistry. 39:7100–7106. 2000. View Article : Google Scholar : PubMed/NCBI
13	Wade PA: Methyl CpG-binding proteins and transcriptional repression. Bioessays. 23:1131–1137. 2001. View Article : Google Scholar : PubMed/NCBI
14	Barr H, Hermann A, Berger J, Tsai HH, Adie K, Prokhortchouk A, Hendrich B and Bird A: Mbd2 contributes to DNA methylation-directed repression of the Xist gene. Mol Cell Biol. 27:3750–3757. 2007. View Article : Google Scholar : PubMed/NCBI
15	Hendrich B and Bird A: Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 18:6538–6547. 1998. View Article : Google Scholar : PubMed/NCBI
16	Shukeir N, Pakneshan P, Chen G, Szyf M and Rabbani SA: Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66:9202–9210. 2006. View Article : Google Scholar : PubMed/NCBI
17	Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han ZG and Szyf M: Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 71:5891–5903. 2011. View Article : Google Scholar : PubMed/NCBI
18	Pakneshan P, Szyf M, Farias-Eisner R and Rabbani SA: Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem. 279:31735–31744. 2004. View Article : Google Scholar : PubMed/NCBI
19	Martin V, Jørgensen HF, Chaubert AS, Berger J, Barr H, Shaw P, Bird A and Chaubert P: MBD2-mediated transcriptional repression of the p14ARF tumor suppressor gene in human colon cancer cells. Pathobiology. 75:281–287. 2008. View Article : Google Scholar : PubMed/NCBI
20	Slack A, Bovenzi V, Bigey P, Ivanov MA, Ramchandani S, Bhattacharya S, tenOever B, Lamrihi B, Scherman D and Szyf M: Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med. 4:381–389. 2002. View Article : Google Scholar : PubMed/NCBI
21	Ivanov MA, Lamrihi B, Szyf M, Scherman D and Bigey P: Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy. J Gene Med. 5:893–899. 2003. View Article : Google Scholar : PubMed/NCBI
22	Liu XY, Tang SH, Wu SL, Luo YH, Cao MR, Zhou HK, Jiang XW, Shu JC, Bie CQ, Huang SM, et al: Epigenetic modulation of insulin-like growth factor-II overexpression by hepatitis B virus X protein in hepatocellular carcinoma. Am J Cancer Res. 5:956–978. 2015.PubMed/NCBI
23	Ataide EC, Boin IF, Almeida JR, Sevá-Pereira T, Stucchi RS, Cardoso AR, Caruy CA and Escanhoela CA: Prognostic factors for hepatocellular carcinoma recurrence: Experience with 83 liver transplantation patients. Transplant Proc. 43:1362–1364. 2011. View Article : Google Scholar : PubMed/NCBI
24	Nobuoka D, Kato Y, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T and Nakatsura T: Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep. 24:521–528. 2010.PubMed/NCBI
25	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
26	Bruix J and Sherman M; Practice Guidelines Committee American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
27	Tandon P and Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI
28	van Malenstein H, van Pelt J and Verslype C: Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer. 47:1789–1797. 2011. View Article : Google Scholar : PubMed/NCBI
29	Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, Kojiro M and Sata M: Microvascular invasion in patients with hepatocellular carcinoma and its predictable clini-copathological factors. Ann Surg Oncol. 15:1375–1382. 2008. View Article : Google Scholar : PubMed/NCBI
30	Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I and Kanematsu T: Predictor for histological micro-vascular invasion of hepatocellular carcinoma: A lesson from 229 consecutive cases of curative liver resection. World J Surg. 34:1034–1038. 2010. View Article : Google Scholar : PubMed/NCBI